ExtendicareEXETF +5.14%76 14-Day RSI is 67.66 as of Jul. 02, 2026. GuruFocus rates EXETF with a GF Score™ of 76/100 and a GF Value™ of $10.07 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 701 Healthcare Providers & Services companies, Extendicare ranks worse than 82.31% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-02), Extendicare's 14-Day RSI is 67.66.
The industry rank for Extendicare's 14-Day RSI or its related term are showing as below:
EXETF's 14-Day RSI is ranked worse than 82.31% of 701
companies
in the Healthcare Providers & Services industry
Industry Median: 48.53
vs EXETF: 67.66
Extendicare (OTCPK:EXETF) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Extendicare 14-Day RSI Related Terms
EXETF vs HCA, THC, DVA: 14-Day RSI Comparison
For the Medical Care Facilities subindustry, Extendicare's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Extendicare 14-Day RSI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Extendicare's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Extendicare's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Extendicare (EXETF) has a 14-Day RSI of 67.66 as of Jul. 02, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Extendicare and its competitors. According to the industry distribution chart, Extendicare ranks #577 out of 701 companies in the Healthcare Providers & Services industry, placing it in the top 82.3%.
Is Extendicare's 14-Day RSI too high?
Extendicare's current 14-Day RSI is 67.66. The Healthcare Providers & Services industry median 14-Day RSI is 48.53. Extendicare's value of 67.66 is 39.4% above this industry median. Based on the distribution chart, Extendicare ranks #577 out of 701 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Extendicare has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Extendicare's 14-Day RSI compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Extendicare ranks #577 out of 701 companies for 14-Day RSI. This places Extendicare in the lower half of its industry. The industry median 14-Day RSI is 48.53. Extendicare's value of 67.66 is 39.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Healthcare Providers & Services company?
The median 14-Day RSI among Healthcare Providers & Services companies is 48.53, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Extendicare's current 14-Day RSI of 67.66 is 39.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Extendicare and its competitors. For the Healthcare Providers & Services industry, the median 14-Day RSI is 48.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Extendicare's current 14-Day RSI is 67.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Extendicare stock overvalued right now?
Based on GuruFocus' analysis, Extendicare (EXETF) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.07, compared to a current price of $25.78 — trading 156% above its estimated fair value. The current 14-Day RSI is 67.66 and 39.4% above the Healthcare Providers & Services industry median of 48.53. Extendicare's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Extendicare (EXETF), the current 14-Day RSI is 67.66 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Extendicare (EXETF) Overvalued in 2026?
Based on GuruFocus' analysis, Extendicare stock appears to be overvalued.
The current stock price of $25.78 is trading 156% above its estimated GF Value™ of $10.07.
GuruFocus considers Extendicare to be Significantly Overvalued.
Key valuation signals for EXETF:
14-Day RSI: 67.66
GF Value™: $10.07 vs. price of $25.78 (156% above fair value)
Industry Position: 39.4% above the Healthcare Providers & Services median (#577 of 701)
No single metric tells the full story. See the EXETF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Extendicare Inc is a senior care provider in Canada, focused on long-term care and home health care. The has three main business segments: Long-term Care (LTC), Home Health Care, and Managed Services. The Long-term Care segment, operating under the Extendicare brand, represents 53 owned homes in Ontario, Alberta and Manitoba. The Home Health Care segment, operating under the ParaMed brand, provides home health care services annually in Ontario, Alberta, Manitoba and Nova Scotia. The Managed Services segment, operating under the Extendicare Assist and SGP Purchasing Partner Network brands, provides management, consulting and group purchasing services to other care providers across Canada. The majority of the company's revenue is derived from the Long-term Care segment.
76GF Score
Get the complete analysis for EXETF
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EXETF has been successfully added to your 